Metabolic Syndrome and Breast Cancer Risk

Burhan Wani; Shiekh Aejaz Aziz; Mohammad Ashraf Ganaie; Mohammad Hussain Mir

doi:10.4103/ijmpo.ijmpo_168_16

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(04): 434-439
DOI: 10.4103/ijmpo.ijmpo_168_16

Original Article

Metabolic Syndrome and Breast Cancer Risk

Authors

Burhan Wani

Department of Medical Oncology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Shiekh Aejaz Aziz

Department of Medical Oncology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Mohammad Ashraf Ganaie

Department of Endocrinology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India
Mohammad Hussain Mir

Department of Medical Oncology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu and Kashmir, India

Abstract

als PDF herunterladen

Abstract

Objective: The study was meant to estimate the prevalence of metabolic syndrome in patients with breast cancer and to establish its role as an independent risk factor on occurrence of breast cancer. Materials and Methods: Fifty women aged between 40 and 80 years with breast cancer and fifty controls of similar age were assessed for metabolic syndrome prevalence and breast cancer risk factors, including age at menarche, reproductive status, live births, breastfeeding, and family history of breast cancer, age at diagnosis of breast cancer, body mass index, and metabolic syndrome parameters. Results: Metabolic syndrome prevalence was found in 40.0% of breast cancer patients, and 18.0% of those in control group (P = 0.02). An independent and positive association was seen between metabolic syndrome and breast cancer risk (odds ratio = 3.037; 95% confidence interval 1.214–7.597). Conclusions: Metabolic syndrome is more prevalent in breast cancer patients and is an independent risk factor for breast cancer.

Keywords

Breast cancer - metabolic syndrome - risk factor

PDF (461 kb)

Referenzen

References
1 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and itscomplications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.
2 Sathyaprakash R, Henry RR. Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep 2002;2:416-22.
3 Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Examination Survey (NHANES III), National Cholesterol Education Program (NCEP), et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-4.
4 Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: A review of the current evidence. Am J Clin Nutr 2007;86:s823-35.
5 Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007;8:395-408.
6 Stoll BA, Secreto G. New hormone-related markers of high risk to breast cancer. Ann Oncol 1992;3:435-8.
7 Folsom AR, Kaye SA, Prineas RJ, Potter JD, Gapstur SM, Wallace RB, et al. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women. Am J Epidemiol 1990;131:794-803.
8 Huang Z, Willett WC, Colditz GA, Hunter DJ, Manson JE, Rosner B, et al. Waist circumference, waist: Hip ratio, and risk of breast cancer in the nurses' health study. Am J Epidemiol 1999;150:1316-24.
9 den Tonkelaar I, Seidell JC, Collette HJ. Body fat distribution in relation to breast cancer in women participating in the DOM-project. Breast Cancer Res Treat 1995;34:55-61.
10 Sonnenschein E, Toniolo P, Terry MB, Bruning PF, Kato I, Koenig KL, et al. Body fat distribution and obesity in pre- and postmenopausal breast cancer. Int J Epidemiol 1999;28:1026-31.
11 Bani IA, Williams CM, Boulter PS, Dickerson JW. Plasma lipids and prolactin in patients with breast cancer. Br J Cancer 1986;54:439-46.
12 Schreier LE, Berg GA, Basilio FM, Lopez GI, Etkin AE, Wikinski RL, et al. Lipoprotein alterations, abdominal fat distribution and breast cancer. Biochem Mol Biol Int 1999;47:681-90.
13 Høyer AP, Engholm G. Serum lipids and breast cancer risk: A cohort study of 5,207 Danish women. Cancer Causes Control 1992;3:403-8.
14 Gaard M, Tretli S, Urdal P. Risk of breast cancer in relation to blood lipids: A prospective study of 31,209 Norwegian women. Cancer Causes Control 1994;5:501-9.
15 Törnberg SA, Holm LE, Carstensen JM. Breast cancer risk in relation to serum cholesterol, serum beta-lipoprotein, height, weight, and blood pressure. Acta Oncol 1988;27:31-7.
16 Manjer J, Kaaks R, Riboli E, Berglund G. Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: A prospective study within the malmö preventive project. Eur J Cancer Prev 2001;10:33-42.
17 Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schünemann HJ, et al. Fasting glucose is a risk factor for breast cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 2002;11:1361-8.
18 Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR. Serum insulin and glucose levels and breast cancer incidence: The atherosclerosis risk incommunities study. Am J Epidemiol 2002;156:349-52.
19 Lawlor DA, Smith GD, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: Findings from the British women's heart and health study. Cancer Causes Control 2004;15:267-75.
20 Benson EA, Holdaway IM. Regulation of insulin binding to human mammary carcinoma. Cancer Res 1982;42:1137-41.
21 Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992;52:3924-30.
22 Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990;50:48-53.
23 Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, et al. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res 1992;52:3636-41.
24 Kaaks R. Nutrition, hormones, and breast cancer: Is insulin the missing link? Cancer Causes Control 1996;7:605-25.
25 Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 2002;20:42-51.
26 Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999;20:535-82.
27 Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R, et al. Serum sex hormone levels after menopause and subsequent breast cancer. J Natl Cancer Inst 1996;88:291-6.
28 Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol 2001;45:S116-24.
29 McTernan PG, Anwar A, Eggo MC, Barnett AH, Stewart PM, Kumar S, et al. Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int J Obes Relat Metab Disord 2000;24:875-81.
30 Cauley JA, Gutai JP, Kuller LH, LeDonne D, Powell JG. The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol 1989;129:1120-31.
31 Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26.
32 Sherif K, Kushner H, Falkner BE. Sex hormone-binding globulin and insulin resistance in African-American women. Metabolism 1998;47:70-4.
33 Golden SH, Ding J, Szklo M, Schmidt MI, Duncan BB, Dobs A, et al. Glucose and insulincomponents of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: The atherosclerosis risk incommunities study. Am J Epidemiol 2004;160:540-8.
34 Brismar K, Hilding A, Lindgren B. Regulation of IGFBP-1 in humans. Prog Growth Factor Res 1995;6:449-56.
35 Norat T, Dossus L, Rinaldi S, Overvad K, Grønbaek H, Tjønneland A, et al. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. Eur J Clin Nutr 2007;61:91-8.
36 Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R, Rosenfeld R, et al. Insulin therapy and GH-IGF-I axis disorders in diabetes: Impact of glycaemic control and hepatic insulinization. Diabetes Metab 1996;22:245-50.
37 Tollet P, Enberg B, Mode A. Growth hormone (GH) regulation of cytochrome P-450IIC12, insulin-like growth factor-I (IGF-I), and GH receptor messenger RNA expression in primary rat hepatocytes: A hormonal interplay with insulin, IGF-I, and thyroid hormone. Mol Endocrinol 1990;4:1934-42.
38 Panno ML, Salerno M, Pezzi V, Sisci D, Maggiolini M, Mauro L, et al. Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells. J Cancer Res Clin Oncol 1996;122:745-9.
39 Campagnoli C, Pasanisi P, Peris C, Berrino F. Insulin-like growth factor-I and breast cancer: Epidemiological and clinical data. Breast Cancer: Prognosis, Treatment, and Prevention. In: Jorge R. Pasqualini, editors. CRC Press 2008. p. 323-42.
40 Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
41 Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-32.
42 Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG, et al. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2007;16:763-8.
43 Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European prospective investigation into cancer and nutrition (EPIC). Endocr Relat Cancer 2006;13:593-605.
44 Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev 2007;28:763-77.
45 Siemińska L, Wojciechowska C, Foltyn W, Kajdaniuk D, Kos-Kudła B, Marek B, et al. The relation of serum adiponectin and leptin levels to metabolic syndrome in women before and after the menopause. Endokrynol Pol 2006;57:15-22.
46 Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: Implications for the etiology of breast cancer. Breast Cancer Res 2002;4:65-9.
47 Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007;14:189-206.
48 Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004;68:975-81.
49 Franceschi S, la Vecchia C, Negri E, Parazzini F, Boyle P. Breast cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 1990;26:781-5.
50 de Waard F, Baanders-van Halewijn EA. A prospective study in general practice on breast-cancer risk in postmenopausal women. Int J Cancer 1974;14:153-60.
51 Moseson M, Koenig KL, Shore RE, Pasternack BS. The influence of medical conditions associated with hormones on the risk of breast cancer. Int J Epidemiol 1993;22:1000-9.
52 Furberg AS, Jasienska G, Bjurstam N, Torjesen PA, Emaus A, Lipson SF, et al. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA study. Cancer Epidemiol Biomarkers Prev 2005;14:33-40.
53 Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M, Tracy RP, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:1147-54.
54 Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 1991;254:573-6.
55 Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 1981;240:E630-9.
56 Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. J Clin Invest 1980;65:717-21.
57 MacGorman LR, Rizza RA, Gerich JE. Physiological concentrations of growth hormone exert insulin-like and insulin antagonistic effects on both hepatic and extrahepatic tissues in man. J Clin Endocrinol Metab 1981;53:556-9.
58 Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med 1990;8:583-99.
59 Sipe HJ Jr., Jordan SJ, Hanna PM, Mason RP. The metabolism of 17 beta-estradiol by lactoperoxidase: A possible source of oxidative stress in breast cancer. Carcinogenesis 1994;15:2637-43.
60 Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996;347:444-5.
61 Kitahara M, Eyre HJ, Lynch RE, Rallison ML, Hill HR. Metabolic activity of diabetic monocytes. Diabetes 1980;29:251-6.
62 Armstrong D, al-Awadi F. Lipid peroxidation and retinopathy in streptozotocin-induced diabetes. Free Radic Biol Med 1991;11:433-6.